首页> 外文期刊>Journal of drugs in dermatology: JDD >Efficacy and tolerability assessment of a topical formulation containing copper sulfate and Hypericum perforatum on patients with herpes skin lesions: A comparative, randomized controlled trial
【24h】

Efficacy and tolerability assessment of a topical formulation containing copper sulfate and Hypericum perforatum on patients with herpes skin lesions: A comparative, randomized controlled trial

机译:含有硫酸铜和贯叶连翘的局部用药对疱疹皮肤病变患者的疗效和耐受性评估:一项比较性,随机对照试验

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Topical Acyclovir has moderate efficacy on recurrent HSV symptoms, requiring repeat applications for several days. Topical Dynamiclear, which requires only a single dose application, may provide a more effective and convenient treatment option for symptomatic management of HSV. Objectives: The study assessed the comparative efficacy and tolerability of a single use, topical formulation containing copper sulfate pentahydrate and Hypericum perforatum that is marketed as Dynamiclear? to a topical 5% Acyclovir cream standard preparation and use. Methods: A prospective, randomized, multi-centered, comparative, open-label clinical study was conducted. A total of 149 participants between 18 and 55 years of age with active HSV-1 and HSV-2 lesions were recruited for the 14-day clinical trial. Participants were randomized into two groups: A (n=61), those receiving the Dynamiclear formulation, and B (n=59), those receiving 5% Acyclovir. Efficacy parameters were assessed via physical examination at baseline (day 1), day 2, 3, 8, and 14. Laboratory safety tests were conducted at baseline and on day 14. Results: Use of the Dynamiclear formulation was found to have no significant adverse effects and was well tolerated by participants. All hematological and biochemical markers were within normal range for the Dynamiclear group. Statistically, odds for being affected by burning and stinging sensation were 1.9 times greater in the Acyclovir group in comparison to the Dynamiclear group. Similarly, the odds of being affected by symptoms of acute pain, erythema and vesiculation were 1.8, 2.4, and 4.4 times higher in the Acyclovir group in comparison to the Dynamiclear group. Conclusions: The Dynamiclear formulation was well tolerated, and efficacy was demonstrated in a number of measured parameters, which are helpful in the symptomatic management of HSV-1 and HSV-2 lesions in adult patients. Remarkably, the effects seen from this product came from a single application.
机译:背景:阿昔洛韦局部治疗对复发性HSV症状具有中等疗效,需要重复应用数天。仅需单剂量应用的局部Dynamiclear可以为HSV的症状管理提供更有效,更方便的治疗选择。目的:该研究评估了含有五水硫酸铜和贯叶连翘的一次性使用局部制剂的相对功效和耐受性,该制剂以Dynamiclear?局部用5%阿昔洛韦乳膏标准品配制和使用。方法:进行了一项前瞻性,随机,多中心,比较,开放标签的临床研究。为期14天的临床试验共招募了149位18-55岁的活跃HSV-1和HSV-2病变参与者。参加者被随机分为两组:A(n = 61),接受Dynamiclear制剂; B(n = 59),接受5%阿昔洛韦。在基线(第1天),第2、3、8和14天通过体格检查评估功效参数。在基线和第14天进行了实验室安全性测试。结果:发现使用Dynamiclear制剂没有明显不良反应效果,并且被参与者很好地耐受。 Dynamiclear组的所有血液学和生化指标均在正常范围内。从统计学上讲,与Dynamiclear组相比,阿昔洛韦组受烧伤和刺痛感影响的几率是1.9倍。同样,与Dynamiclear组相比,阿昔洛韦组受急性疼痛,红斑和囊泡症状影响的几率分别高1.8倍,2.4倍和4.4倍。结论:Dynamiclear制剂具有良好的耐受性,并在许多测量参数中证明了其功效,这有助于对成年患者HSV-1和HSV-2病变进行对症处理。值得注意的是,从该产品看到的效果来自单一应用程序。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号